In addition, retrospective analysis revealed that EGFR-TKIs plus chemotherapy conferred a significantly higher ORR (65.5 vs. 38.9%, p = 0.046), prolonged PFS (7.2 vs. 4.7 months; p = 0.008) and a longer OS (18.5 vs. 14.2 months; p = 0.107) compared to TKIs alone in advanced NSCLC patients with EGFR mutations and BIM deletion polymorphism (176). This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.